Within3 Announces the Evolution of Industry-First Insights Management Platform

The amplified iteration of the platform transforms the potential for market visibility, research collaboration and business decision-making in life science CLEVELAND & LONDON–(BUSINESS WIRE)–Within3 announces new enhancements to its industry-first insights management platform for pharmaceutical and medical device companies. With more than 40 engagement applications across the platform, life science organizations can now better understand … [Read more…]

H.I.G. Capital Completes Recapitalization of Navitas Life Sciences

MIAMI–(BUSINESS WIRE)–#BlueChipClients–H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with over $50 billion of equity capital under management, is pleased to announce that one of its affiliates has completed the recapitalization of Navitas Life Sciences (“Navitas” or the “Company”). Headquartered in Princeton, NJ, Navitas is a global technology-enabled clinical research organization (CRO) providing outsourced … [Read more…]

Global EMC Filtration Market (2022 to 2027) – Increasing Adoption of Electric Vehicles Presents Opportunities – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “EMC Filtration Market by Product Type (EMC Filters (1-Phase EMC Filters, 3-Phase EMC Filters, DC Filters, IEC Inlets, Chokes), Power Quality Filters (Passive Harmonic Filters, Active Harmonic Filters, Output Filters, Reactors)) – Global Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering. The EMC filtration market is expected to grow from USD … [Read more…]

Revitalist and Wake Network Enter Joint Venture Offering National and International Access to Psychedelics for Veterans

VANCOUVER, British Columbia–(BUSINESS WIRE)–#education–REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company”) (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO), Revitalist and Wake Network, Inc. will now be jointly offering ketamine infusions in the United States and psilocybin clinical retreats internationally with a special focus on Veteran’s ethical need for access, establishing the world’s first international center … [Read more…]

One Biosciences Initiates LARYCARE Clinical Study, Its Second Discovery Program

The LARYCARE study aims at discovering new predictive biomarkers to treatment response and at developing new potential precision therapies in the larynx and hypopharynx carcinoma This study follows One Biosciences’ first discovery program initiated a year ago in partnership with Institut Curie investigating high-grade serous ovarian cancer The initiation of this study follows the completion … [Read more…]

ONWARD Reports Positive Topline Results from a Pivotal Study to Restore Arm and Hand Function in People With Spinal Cord Injury

Up-LIFT study achieves primary endpoint: Statistically significant and clinically meaningful improvement in upper extremity strength and functioni Improvement in arm and hand function is the highest priority among people with tetraplegiaii Up-LIFT is the first large-scale clinical study of non-invasive spinal cord stimulation technology ONWARD plans to submit for marketing approval in the U.S. and … [Read more…]

Revance Announces Pricing of $200.0 Million Upsized Public Offering of Common Stock

NASHVILLE, Tenn.–(BUSINESS WIRE)–Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings (“Revance” or the “Company”), today announced the pricing of an upsized underwritten public offering of 8,000,000 shares of its common stock. The shares of common stock are being offered at a public offering price of $25.00 … [Read more…]

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in China

BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969) announced today that the Company has received Investigational New Drug (IND) approval of clinical trial from the NMPA (National Medical Products Administration) for its B-cell lymphoma-2 (BCL2) inhibitor ICP-248, which is the Company’s fifth innovative drug to enter the clinical stage in the field of hematology, and also the 13th … [Read more…]

CANbridge Pharmaceuticals to Participate in Two Investor Conferences in September

BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–CANbridge Pharmaceuticals, Inc. (HKEX:1228) , a China and U.S.-based global biopharmaceutical company committed to the research, development and commercialization of transformative therapies to treat rare diseases and oncology, today announced that it will be participating in two upcoming investor conferences. Morgan Stanley 20th Annual Global Healthcare Conference (New York) CEO, James … [Read more…]